Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for Pegunigalsidase Alfa

PR NewswireDec 9 19:30

Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript Summary

Futu NewsNov 15 00:35 · Conference Call

Protalix BioTherapeutics Reports Profit In Q3; Announces Positive Phase 1 Data For PRX-115

RTTNewsNov 14 20:48

Protalix Biotherapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 14 20:07 · Announcements

Protalix Biotherapeutics | 8-K: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

SECNov 14 20:02

Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $18M

MT NewswiresNov 14 19:52